| Name | Epirubicin hydrochloride |
|---|---|
| Synonyms |
IRUBICIN HYDROCHLORIDE STANDD
irubicin hydrochloride / irubicin hcl 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.α.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride irubicin HCl irubicin hydrochloride irubicin Hydrochloride 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S) (8s-cis)-rochlorid (8R,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-7-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,1 irubicin HydrochlorideQ: What is irubicin Hydrochloride Q: What is the CAS Number of irubicin Hydrochloride Q: What is the storage condition of irubicin Hydrochloride Q: What e the applications of irubicin Hydrochloride (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride (1:1) EINECS 260-145-2 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-alpha-l-abino-hexopyranosy i-Doxorubicin HCl Fmorubicin-RTU irubicin Hydrochloride RS ELLENCE; PHMORUBICIN; IRUBICIN EBEWE irubicin hydrochloride (Ellence), Topoisomerase II inhibitor EPIRUBICIN HCl 5,12-naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, hydrochloride irubicin hydrochloride, (HPLC) (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride (1:1) irubicin hydrochloride(4'-idoxorubicin) Pidorubicin hydrochloride Ellence irubicin hydrochloride CRS irubicin hydrochloride, >= (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride (Doxorubicin Impurity) (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride (8S,10S)-10-{[(2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen-5,12-dionhydrochlorid (8R,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-7-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione cis)-10-[(3-Amino-2,3,6-tridesoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacen-5,12-dionhydrochlorid (8S,10S)-10-(((2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-tri 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis) Adrial (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedionehydrochloride irubin HCI irubicin, Hydrochloride Salt irubicin Hydrochloride R.HCl) 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-, hydrochloride (1:1) irubiein Hydrochloride irubicin hydrochloride //BP irubicin Hydrochloride - - Calbiochem idoxorubicin hydrochloride (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione, hydrochloride (1:1) 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-abino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S) irubicin hydrochloride, 10 mM in DMSO (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride irubicin HCl API Epirubicin (hydrochloride) (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride (8S-cis)-4'-idoxorubicin Hydrochloride 8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-l)oxy)-hyd irubicin Ebewe irubicin (IMI 28) HCl irubicinHc,L5 Ebewe (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride irubicin HCl (4'-idoxorubicin) Ellence, Fmorubicin, Phmorubicin 5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-abino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S) 4’-i-adriamycinhydrochloride |
| Description | Epirubicin (hydrochloride) is a semisynthetic L-arabino derivative of doxorubicin, and an antineoplastic agent by inhibiting Topoisomerase. |
|---|---|
| Related Catalog | |
| Target |
Topoisomerase |
| In Vitro | Epirubicin, like doxorubicin, exerts its antitumor effects by complex with DNA, resulting in damage to DNA and interference with the synthesis of DNA, RNA, and proteins. Epirubicin may also affect the integrity and activity of cellular membranes. Maximal cell kill caused by Epirubicin occurs during the S phase of the cell cycle. With higher concentrations effects are also seen in early G2 as well as G1 and M phases[1]. Epirubicin display antineoplastic activity against most cancer cells. Epirubicin is cytotoxic to Hepatoma G2 cells with IC50 of 1.6 μg/mL at 24 hr. 1.6 μg/mL Epirubicin induces apoptosis of Hep G2 cells, and higher activity of catalase by 50%, Se-dependent glutathione peroxidase by 110%, Cu, Zn-superoxide dismutase by 172% and Mn-superoxide dismutase by 135%. Epirbicin increases the cellular expression of NADPH-CYP 450 reductase, and reduces GST-π expression[2]. |
| In Vivo | Epirubicin are clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on[3]. Epirubicin at a dose of 3.5 mg/kg suppresses tumor mass of human breast tumor xenograft R-27 by 74.4 %[4]. |
| Cell Assay | Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37°C, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded. |
| References |
[3]. Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69. |
| Density | 1.61g/cm3 |
|---|---|
| Boiling Point | 810.3ºC at 760 mmHg |
| Melting Point | 185ºC dec |
| Molecular Formula | C27H30ClNO11 |
| Molecular Weight | 579.980 |
| Flash Point | 443.8ºC |
| Exact Mass | 579.150757 |
| PSA | 206.07000 |
| LogP | 1.50360 |
| Index of Refraction | 1.709 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H340-H350-H360 |
| Precautionary Statements | P201-P280-P301 + P312 + P330-P308 + P313 |
| Hazard Codes | Xn |
| Risk Phrases | 22-63-62-46-40 |
| Safety Phrases | 36/37/38-45-46 |
| RIDADR | NONH for all modes of transport |
| RTECS | QI9295750 |
| HS Code | 2932999099 |
| HS Code | 2932999099 |
|---|---|
| Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |